Reach Us +1-947-333-4405


Apple Cider Vinegar (ACV®) Displays Potent Antibiotic Activity Directly Against Escherichia Coli And Candida Albicans And Within In Vitro Monocytes Exposed To Microbes By Inhibiting Inflammatory Cytokine Secretion | 71847
ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Google scholar citation report
Citations : 1224

Journal of Infectious Diseases & Therapy received 1224 citations as per google scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Open J Gate
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • Publons
  • Euro Pub
Share This Page

Apple cider vinegar (ACV®) displays potent antibiotic activity directly against Escherichia coli and Candida albicans and within in vitro monocytes exposed to microbes by inhibiting inflammatory cytokine secretion

3rd Annual Congress on Infectious Diseases

Darshna Yagnik

Middlesex University, UK

ScientificTracks Abstracts: J Infect Dis Ther

DOI: 10.4172/2332-0877-C1-026

Introduction: Extraintestinal pathogenic Escherichia coli (E-coli) are the most frequent cause of blood borne, urinary tract and hospital acquired infections. Candida albicans infection can also pose a huge threat especially following transplantation and to immune compromised patients. Globally there has never been a more desperate time for novel anti-microbial agents to target microbes and multi drug resistance from bacterial or fungal associated infections. Aim: The aim of this study was to investigate the potential anti-microbial effects of ACV®. We used microbial strains: E. coli strain 6571, C. albicans strain 90828 purchased from ATCC. Methodology: We tested the effect of commercial ACV® directly on microbial cultures over a 24 hour period, measuring inhibition zones. We also looked at whether ACV® could have an anti-inflammatory effect in vitro. This was tested using human blood derived monocytes which were incubated with microbes and AVC®. The collected supernatants were analyzed for proinflammatory cytokine secretion by ELISA. Results: When monocytes were cultured with both microbes they secreted TNFα and IL-1β. ACV® was able to significantly inhibit E-coli growth demonstrated by the results of direct co-culture with each of the microbial inoculums and ACV® in varying concentrations. The zone of inhibition with the addition of ACV® to each of the microbes varied dose dependently ACV® concentration. For Candida albicans undiluted ACV® had the strongest effect, whereas on E-coli cultures, the most potent effect was visible at lower dilutions including 1/1000 dilution of the neat solution (p<0.05). When monocytes were cultured with both microbes they secreted inflammatory cytokines (TNFα, IL-1β) ACV® was effective in significantly inhibiting inflammatory cytokine secretion in human peripheral blood monocytes cultured with E. coli and Candida albicans Conclusion and significance: ACV® displayed potent anti-microbial and anti-inflammatory activity against E. coli and Candida albicans. We propose that ACV® could be potentially therapeutic in cases of antibiotic resistance and sepsis.

Darshna Yagnik is a Lecturer of Immunology and Biomedical Sciences at Middlesex University. Her research is based on human in vitro models of mononuclear cell differentiation and their role in inflammatory pathways and particularly the resolution phase of inflammation.